A phase I study of HT-3951 for the treatment of neurodegenerative disorders
Latest Information Update: 13 Apr 2015
At a glance
- Drugs HT 3951 (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions
- 13 Apr 2015 New trial record
Latest Information Update: 13 Apr 2015